PolyPid (PYPD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $132.25M
Last updated: Nov 17, 2026 at 11:05 AM ET
PolyPid (PYPD) Competitors
The companies most similar to PolyPid are PDS Biotechnology (PDSB), Protalix Biotherapeutics (PLX) and Pyxis Oncology (PYXS). By market cap, PolyPid ranks 8th of the 13 companies on this page; Protalix Biotherapeutics (PLX) is the largest at $257.17M.
Peer Comparison
PYPD's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| PolyPid (PYPD) | $132.25M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| PDS Biotechnology Corp (PDSB) | $107.07M | N/A | N/A | 0.0% | -149.8% | 0.0% | 0.00% |
| Protalix Biotherapeutics Inc (PLX) | $257.17M | 12.1x | 2.9x | 24.3% | N/A | 22.8% | 0.00% |
| Pyxis Oncology Inc (PYXS) | $188.98M | N/A | 11.6x | 0.0% | N/A | 0.0% | 0.00% |
| Pmv Pharmaceuticals Inc (PMVP) | $95.93M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Protara Therapeutics Inc (TARA) | $155.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| LENZ Therapeutics Inc (LENZ) | $129.77M | N/A | 9.7x | 0.0% | N/A | -72.9% | 0.00% |
| Sol Gel Technologies Ltd (SLGL) | $180.46M | N/A | 125.4x | 0.0% | N/A | -96.6% | 0.00% |
| Atrium Therapeutics, Inc. Common Stock (RNA) | $162.00M | N/A | 3.3x | -180.9% | -44.5% | 24.2% | 0.00% |
| Codexis Inc (CDXS) | $127.13M | N/A | N/A | -21.8% | N/A | 124.0% | 0.00% |
| ProQR Therapeutics BV (PRQR) | $199.28M | N/A | 6.1x | -228.2% | N/A | 120.4% | 0.00% |
| Molecular Partners AG ADR (MOLN) | $112.71M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Oramed Pharmaceuticals Inc (ORMP) | $161.33M | 4.3x | N/A | 0.0% | N/A | -100.0% | 6.41% |
| Peer median | $158.55M | 8.2x | 7.9x | 0.0% | -97.1% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to PolyPid, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| PDS Biotechnology Corp (PDSB) | PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies. | PDSB competitors |
| Protalix Biotherapeutics Inc (PLX) | Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its... | PLX competitors |
| Pyxis Oncology Inc (PYXS) | Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb)... | PYXS competitors |
| Pmv Pharmaceuticals Inc (PMVP) | PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53... | PMVP competitors |
| Protara Therapeutics Inc (TARA) | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment... | TARA competitors |
| LENZ Therapeutics Inc (LENZ) | LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders... | LENZ competitors |
| Sol Gel Technologies Ltd (SLGL) | Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological... | SLGL competitors |
| Atrium Therapeutics, Inc. Common Stock (RNA) | Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. | RNA competitors |
| Codexis Inc (CDXS) | Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California. | CDXS competitors |
| ProQR Therapeutics BV (PRQR) | ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. | PRQR competitors |
| Molecular Partners AG ADR (MOLN) | Molecular Partners AG is a clinical-stage biopharmaceutical company. The company is headquartered in Schlieren, Switzerland. | MOLN competitors |
| Oramed Pharmaceuticals Inc (ORMP) | Oramed Pharmaceuticals Inc. is dedicated to the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally... | ORMP competitors |
Frequently Asked Questions About PYPD
Who are PolyPid's main competitors?
The companies most similar to PolyPid include PDS Biotechnology (PDSB), Protalix Biotherapeutics (PLX), Pyxis Oncology (PYXS), Pmv Pharmaceuticals (PMVP) and Protara Therapeutics (TARA), listed from the closest match.
Who is PolyPid's biggest competitor?
Protalix Biotherapeutics (PLX) is the largest of the similar companies at $257.17M; PDS Biotechnology (PDSB) is the closest match by business profile, size, sector and industry.
How does PYPD stock compare with its competitors?
PYPD's net margin is 0.0% against a peer median of 0.0%.
Which of PolyPid's competitors pays a higher dividend?
PolyPid pays no dividend. Oramed Pharmaceuticals (ORMP) has a higher forward dividend yield; Oramed Pharmaceuticals (ORMP) has the highest at 6.41%.
Is PolyPid bigger than its competitors?
No. PolyPid is 8th by market cap among the 13 companies on this page; the largest is Protalix Biotherapeutics (PLX) at $257.17M.
PYPD pages: Overview, Earnings, Forecast, Competitors